Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients
- PMID: 29475102
- DOI: 10.1016/j.psychres.2018.02.013
Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients
Abstract
We investigated the rates of current and past benzodiazepine (BZD) use in a sample of 102 subjects attending specialized anxiety disorder clinics, including panic disorder (PD; N = 36), social anxiety disorder (SAD; N = 28) and obsessive-compulsive disorder (OCD; N = 38) patients. Almost 56% of the entire sample was using BZDs at the moment of the assessment, and 74.5% described having used them at some point during their lifetimes. The duration of psychiatric treatment and a lifetime history of PD, but not any other "transdiagnostic" measure of severity (such as the Panic and Agoraphobia Scale, the Social Phobia Inventory, the Dimensional Obsessive-Compulsive Scale, the Anxiety Sensitivity Index-36, and the Beck Inventories) were independent risk factors for current prescription of BZDs. Patients who continued to use BZDs differed from patients who stopped them by being older (both currently and when firstly seen in the clinic), by having a later age at onset of their most significant anxiety disorder, by being more agoraphobic/avoidant, and by believing to be less capable of stopping their BZDs for the fear of not being able to sleep.
Keywords: Benzodiazepines; Obsessive-compulsive disorder; Panic disorder; Self-efficacy; Social phobia; Substance abuse.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Duration of untreated illness in a cross-diagnostic sample of obsessive-compulsive disorder, panic disorder, and social anxiety disorder.CNS Spectr. 2019 Oct;24(5):526-532. doi: 10.1017/S1092852918001281. CNS Spectr. 2019. PMID: 30419984
-
Autism spectrum disorder, social anxiety and obsessive-compulsive disorders: beyond the comorbidity.BMC Psychiatry. 2025 Jan 13;25(1):37. doi: 10.1186/s12888-024-06340-8. BMC Psychiatry. 2025. PMID: 39806378 Free PMC article.
-
[Validation of a scale for responsibility (Salkovskis Responsibility Scale)].Encephale. 2001 May-Jun;27(3):229-37. Encephale. 2001. PMID: 11488253 French.
-
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis.J Affect Disord. 2017 Aug 15;218:217-226. doi: 10.1016/j.jad.2017.04.068. Epub 2017 Apr 29. J Affect Disord. 2017. PMID: 28477500 Review.
-
Pharmacotherapy of anxious disorders.Hum Psychopharmacol. 2002 Dec;17(8):383-400. doi: 10.1002/hup.435. Hum Psychopharmacol. 2002. PMID: 12457374 Review.
Cited by
-
Biopsychosocial Model Social Anxiety and Substance Use Revised.Curr Psychiatry Rep. 2021 Apr 17;23(6):35. doi: 10.1007/s11920-021-01249-5. Curr Psychiatry Rep. 2021. PMID: 33864136 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous